Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | RHOA | P61586 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 5/20 | 0.42 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2846275 | 0.87 | POLB (0.45) | POLBRHOAMEN1KMT2AALDH1A1 | |
| SCHEMBL2849948 | 0.87 | POLB (0.45) | POLBRHOAMEN1KMT2AALDH1A1 | |
| SCHEMBL2850274 | 0.86 | KAT6A (0.49) | POLBRHOAMEN1KMT2AALDH1A1 | |
| SCHEMBL2850273 | 0.86 | KAT6A (0.49) | POLBRHOAMEN1KMT2AALDH1A1 | |
| SCHEMBL5592323 | 0.84 | POLB (0.42) | POLBRHOAGRM5MEN1KMT2A | |
| SCHEMBL5604174 | 0.83 | POLB (0.43) | POLBMEN1KMT2AALDH1A1KDM2B | |
| SCHEMBL3963250 | 0.78 | HPGD (0.56) | POLBRHOAMEN1KMT2AALDH1A1 | |
| SCHEMBL4755206 | 0.77 | POLB (0.52) | POLBMEN1KMT2AALDH1A1KDM2B | |
| SCHEMBL4748847 | 0.77 | KAT7 (0.44) | — | |
| SCHEMBL2850721 | 0.77 | MEN1 (0.41) | POLBMEN1KMT2AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130471-A1 | Renin Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2010-05-27 | — | — | US | disclosed |
| EP-2167609-A1 | RENIN INHIBITORS | Vitae Pharmaceuticals, Inc. (US) | 2010-03-31 | — | — | EP | disclosed |
| WO-2009096996-A1 | RENIN INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-06 | — | — | WO | disclosed |
| WO-2008124575-A1 | RENIN INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008124577-A1 | RENIN INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130471-A1 | Renin Inhibitors | ACE, REN, DNPEP | POLB 1262/4885RHOA 2661/4885GRM5 1565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.